Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-7000 for refractory focal onset epilepsy
2023-508811-21-00Phase 3Authorised
- Sponsor
- Biohaven Ltd.
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of opakalim in Focal Onset Epilepsy (3 arms), sponsored by Biohaven Ltd. Primary endpoint: 50% responder rate for BHV-7000 75 mg versus placebo. Planned start Sep 2024; status: authorised.
02
Drugs
opakalim
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2023-508811-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508811-21-00.